PBMs began by providing a huge service to payers, but in recent years, they’ve begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?
CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter’s Vraylar sees positive results for bipolar depression
Five things for pharma marketers to know: Thursday, August 17, 2017
Express Scripts to limit opioid coverage; Novo’s diabetes drug lowers glucose levels in trial; startup aims to give doctors access to a patient’s total costs
CVS relies on personalization in its ExtraCare loyalty program